Page last updated: 2024-11-11

glycitein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycitein : A methoxyisoflavone that is isoflavone substituted by a methoxy group at position 6 and hydroxy groups at positions 7 and 4'. It has been isolated from the mycelia of the fungus Cordyceps sinensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5317750
CHEMBL ID513024
CHEBI ID34778
SCHEMBL ID19720
MeSH IDM0229497

Synonyms (40)

Synonym
BIDD:ER0470
AC-998
40957-83-3
7,4'-dihydroxy-6-methoxyisoflavone
glycitein
4h-1-benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4h-1-benzopyran-4-one
4-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-chromen-7-one
bdbm50241530
CHEMBL513024 ,
chebi:34778 ,
LMPK12050104
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one
A825364
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-chromen-4-one
92m5f28tvf ,
unii-92m5f28tvf
S9107
FT-0630616
AKOS015892762
4',7-dihydroxy-6-methoxyisoflavone
SCHEMBL19720
glycitein [usp-rs]
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4h-chromen-4-one
glycitein (constituent of soy isoflavones) [dsc]
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4h-one
Q-100465
HY-N0016
mfcd00016679
DTXSID40193960
glycitein, analytical standard
glycitein, united states pharmacopeia (usp) reference standard
glycitein, >=97% (hplc)
AS-71538
Q3109347
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4h-1-benzopyran-4-one; 7,4 inverted exclamation mark -dihydroxy-6 methoxyisoflavone;glycetein
BCP13270
HMS3886N16
CCG-267294
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4h-1-benzopyran-4-one; 7,4'-dihydroxy-6-methoxyisoflavone; glycetein; glycitein; glycitin aglycon

Research Excerpts

Overview

Glycitein is an isoflavone that reportedly inhibits the proliferation of human breast cancer and prostate cancer cells. It accounts for 5-10% of the total is oflavones in soy food products. Its role in cholesterol regulation is unclear.

ExcerptReferenceRelevance
"Glycitein is an isoflavone that reportedly inhibits the proliferation of human breast cancer and prostate cancer cells. "( Glycitein induces reactive oxygen species-dependent apoptosis and G0/G1 cell cycle arrest through the MAPK/STAT3/NF-κB pathway in human gastric cancer cells.
Feng, YC; Feng, YY; Jin, CH; Ju, XY; Luo, YH; Wang, JR; Yu, CQ; Zang, YQ; Zhai, YQ, 2019
)
3.4
"Glycitein is an O-methylated isoflavone which accounts for 5-10% of the total isoflavones in soy food products. "( Inhibitory effects of O-methylated isoflavone glycitein on human breast cancer SKBR-3 cells.
Bai, Y; Li, J; Liu, YH; Su, JP; Zhang, B, 2015
)
2.12
"Glycitein is a Selective Estradiol Receptor Modulator (SERM) from soy. "( Bioavailability of glycitein relatively to other soy isoflavones in healthy young Caucasian men.
Bennetau-Pelissero, C; Carpaye, A; Chantre, P; Durand, M; Lamothe, V; Martinet, A; Moore, N; Nogues, X; Shinkaruk, S; Vergne, S, 2012
)
2.15
"Glycitein (GLY) is a major isoflavone of soy germ which is used as a functional ingredient to enrich foods with isoflavones as well as a component of soy supplements. "( In vitro and in vivo metabolism of the soy isoflavone glycitein.
Donauer, E; Fabian, EJ; Kulling, SE; Maul, R; Rüfer, CE, 2007
)
2.03
"Glycitein is a minor component in most soy products, and its role in cholesterol regulation is unclear."( Soy milk with a high glycitein content does not reduce low-density lipoprotein cholesterolemia in type II hypercholesterolemic patients.
Bondioli, A; Bosisio, R; Gatti, E; Lovati, MR; Murphy, P; Pazzucconi, F; Sirtori, CR, 2002
)
1.35

Treatment

ExcerptReferenceRelevance
"Glycitein treatment also restored the mitochondrial membrane potential of the rotenone treated SK-N-SH cells."( Glycitein exerts neuroprotective effects in Rotenone-triggered oxidative stress and apoptotic cell death in the cellular model of Parkinson's disease.
Dong, N; Yang, Z, 2022
)
2.89

Pharmacokinetics

The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal women.

ExcerptReferenceRelevance
"We conducted safety studies of purified unconjugated genistein, daidzein, and glycitein, and defined pharmacokinetic parameters for their absorption and metabolism."( Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men.
Black, T; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Heizer, WD; Hill, JM; Jeffcoat, AR; Koch, MA; Thomas, BF; Zeisel, SH, 2002
)
0.54
"The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal women."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.51
" The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.31
" These results support the potential of this method for successful application in pharmacokinetic studies."( Metabolite Identification and Pharmacokinetic Profiling of Isoflavones from Black Soybean in Rats Using Ultrahigh-Performance Liquid Chromatography with Linear-Ion-Trap-Orbitrap and Triple-Quadrupole Tandem Mass Spectrometry.
Bai, J; Guo, Q; Huang, J; Liu, Y; Qiu, X; Su, Z; Wei, M; Zhang, J, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"There are limited reports on the bioavailability and pharmacokinetics of isoflavones in elderly humans and aged animals."( Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Cooke, GM; Gilani, GS; Robertson, P; Sepehr, E, 2009
)
0.35
" The study reports plasma bioavailability and urine excretion of glycitein compared to other soy isoflavones after a unique intake of food supplement based on soy germ containing 55."( Bioavailability of glycitein relatively to other soy isoflavones in healthy young Caucasian men.
Bennetau-Pelissero, C; Carpaye, A; Chantre, P; Durand, M; Lamothe, V; Martinet, A; Moore, N; Nogues, X; Shinkaruk, S; Vergne, S, 2012
)
0.95
" This study investigated whether DJ improves the bioavailability of isoflavones compared to boiled soybean (BS) in sham-operated or ovariectomized (OVX) rats."( Bioavailability of Isoflavone Metabolites After Korean Fermented Soybean Paste (Doenjang) Ingestion in Estrogen-Deficient Rats.
Ahn, J; Ha, TY; Jang, YJ; Jung, CH; Kim, MJ; Lee, DH; Nam, YD; Park, SH; Song, EJ, 2018
)
0.48
" Isoflavone aglycones (IFAs) of soybeans in human diets have poor solubility in water, resulting in low bioavailability and bioactivity."( Enrichment of Polyglucosylated Isoflavones from Soybean Isoflavone Aglycones Using Optimized Amylosucrase Transglycosylation.
Jang, D; Jung, YS; Kim, AT; Kim, DO; Kim, MS; Kim, YJ; Nam, TG; Park, CS; Rha, CS; Seo, DH, 2020
)
0.56

Dosage Studied

Women consume fermented soya milk at a dosage of 40 mg isoflavone. A trend to a greater percentage urinary recovery of daidzein and glycitein was observed among women.

ExcerptRelevanceReference
" At the high glycitein dose (soygerm), plasma concentration at 24 h after dosing suggested a modest gender difference in glycitein bioavailability."( Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity.
Hendrich, S; Murphy, PA; Song, TT; Wang, GJ; Zhang, Y, 1999
)
0.91
" Weaning female B6D2F1 mice were dosed with glycitein (3 mg/day), genistein (3 mg/day), and diethylstilbestrol (DES) (0."( Estrogenic activity of glycitein, a soy isoflavone.
Hendrich, S; Murphy, PA; Song, TT, 1999
)
0.88
" The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.31
" A trend to a greater percentage urinary recovery of daidzein and glycitein was observed among women consuming fermented soya milk at a dosage of 40 mg isoflavone (P=0."( Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soya milk fermented with probiotic bifidobacteria.
Shah, NP; Stojanovska, L; Tsangalis, D; Wilcox, G, 2005
)
0.57
" No significant differences in the bioavailability of daidzein were observed in aged rats dosed with aglycon, glucoside or Novasoy."( Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Cooke, GM; Gilani, GS; Robertson, P; Sepehr, E, 2009
)
0.35
" Similarly, inverse associations with apparent dose-response relationships were found between isoflavone intakes and oesophageal cancer risk."( Soya and isoflavone intakes associated with reduced risk of oesophageal cancer in north-west China.
Binns, CW; Lee, AH; Lei, J; Tang, L; Xu, F; Zhang, T, 2015
)
0.42
" The control group was fed a basal diet containing fresh fish oil, and the other two groups received the same diet except for the substitution with the same dosage of oxidized fish oil alone or with ISF (oxidized fish oil plus ISF)."( Effects of soybean isoflavone on intestinal antioxidant capacity and cytokines in young piglets fed oxidized fish oil.
Gao, KG; Hu, YJ; Huang, L; Jiang, ZY; Ma, XY; Wang, L; Yang, XF; Zheng, CT,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
phytoestrogenAny compound produced by a plant that happens to have estrogenic activity.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
methoxyisoflavoneMembers of the class of isoflavones with at least one methoxy substituent.
7-hydroxyisoflavoneThe simplest member of the class of 7-hydroxyisoflavones that is isoflavone with a hydroxy substituent at position 7.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase II - Conjugation of compounds73122
Glucuronidation718

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseMus musculus (house mouse)IC50 (µMol)500.00000.03002.21045.2300AID457084
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)841.30000.00132.81389.8200AID387151; AID387152
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1656436Inhibition of beta-glucuronidase (unknown origin)2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID387150Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID377876Antifungal activity against Giardia intestinalis ATCC 30888 at 10 ug/mL after 48 hrs by XTT assay2000Journal of natural products, Oct, Volume: 63, Issue:10
Antigiardial activity of isoflavones from Dalbergia frutescens bark.
AID402363Activity at human estrogen receptor expressed in transgenic Arabidopsis plant at 5 uM by pER8-GFP reporter assay2005Journal of natural products, Jul, Volume: 68, Issue:7
The transgenic Arabidopsis plant system, pER8-GFP, as a powerful tool in searching for natural product estrogen-agonists/antagonists.
AID387152Inhibition of xanthine oxidase assessed as decrease of uric acid generation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID457084Inhibition of tyrosinase in mouse Melan-a cells by ELISA2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
AID456318DPPH radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID387151Inhibition of xanthine oxidase assessed as decrease of superoxide generation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID456316ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID457086Antioxidant activity assessed as superoxide radical scavenging activity after 2 mins by NBT reduction assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
AID457085Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (149)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (5.37)18.2507
2000's70 (46.98)29.6817
2010's59 (39.60)24.3611
2020's12 (8.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.99 (24.57)
Research Supply Index5.16 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (34.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (10.19%)5.53%
Reviews8 (5.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (84.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]